This really is becoming a bore. You have had many links provided for you to find this information but you haven't bothered to read through.
To what information would this relate? Nanomaterials and nanotechnologies have the potential to help create new product testing methods that avoid the use of laboratory animals.
Perhaps the reference to nanomaterials needing to be tested themselves? Do you know the difference between prefer and require? If what is required will not allow the use of what is preferred the preferred aspect is eliminated.
If there isn't an alternative it won't be used until such a time there is an alternative.
Unless the deadline is extended until there are alternatives.
If there is a need, the toxicity test using in vitro methods will be used without alternatives.
In exceptional circumstances, where serious concerns arise as regards the safety of an existing cosmetic ingredient, a Member State may request the Commission to grant a derogation from paragraph 1. The request shall contain an evaluation of the situation and indicate the measures necessary. On this basis, the Commission may, after consulting the SCCS and by means of a reasoned decision, authorise the derogation. That authorisation shall lay down the conditions associated with this derogation in terms of specific objectives, duration and reporting of the results.
A derogation shall be granted only where:
the ingredient is in wide use and cannot be replaced by another ingredient capable of performing a similar function;(b)
the specific human health problem is substantiated and the need to conduct animal tests is justified and is supported by a detailed research protocol proposed as the basis for the evaluation.
The decision on the authorisation, the conditions associated with it and the final result achieved shall be part of the annual report presented by the Commission in accordance with Article 35.
The measures referred to in the sixth subparagraph, designed to amend non-essential elements of this Regulation, shall be adopted in accordance with the regulatory procedure with scrutiny referred to in Article 32(3).
The only substances that can be used are them that are already safety assessed, there is a large database listing them.
Can you show where this limitation is presented? There are products which require continuing toxicity testing as part of the production process.